

Literatura ACTA MEDICINAE

11–13/2020 Onkologie | Hematoonkologie | Hematologie

- 3 **Nové možnosti léčby triple negativního karcinomu prsu**
MUDr. Miloš Holánek Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 3 **Adjuvantní léčba HER pozitivního karcinomu prsu**
MUDr. Martina Zimovjanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha
- 3 **Algoritmus léčby metastatického karcinomu ledviny v roce 2020**
doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 4 **Možnosti imuno-onkologické léčby v terapii malobuněčných karcinomů plic**
prof. MUDr. Miloš Pešek, CSc. Klinika pneumologie a ftizeologie, FN a LF UK Plzeň
- 4 **Virtuální konference ASCO 2020 a léčba karcinomu plic**
MUDr. Leona Koubková Pneumologická klinika UK 2 LF a FN v Motole, Praha
- 4 **Durvalumab po chemoradioterapii nemalobuněčného plicního karcinomu – mění se paradigma konsolidační léčby**
MUDr. Gabriela Krákorová, Ph.D. Klinika pneumologie a ftizeologie, FN a LF UK, Plzeň
MUDr. Radovan Vojtíšek, Ph.D. Onkologická a radioterapeutická klinika, FN a LF UK, Plzeň
- 5 **Atezolizumab a chemoterapie v první linii léčby extenzivního malobuněčného karcinomu plic – studie IMpower133**
MUDr. Libor Havel Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha
- 5 **Využitie amfotericínu B vo forme lipidového komplexu v liečbe invazívnej aspergilózy – kazuistika**
MUDr. Ladislav Sopko, PhD. Klinika Hematológie a transfuziológie, LFUK, SZU a Univerzitná nemocnica, Bratislava
- 5 **Liečba invazívnej pľúcnej mykotickej infekcie v praxi u onkohematologického pacienta – kazuistika**
MUDr. Tomáš Guman, PhD. Klinika hematológie a onkohematológie (KHaOH), Univerzitná nemocnica L. Pasteura a LF UPJŠ, Košice
- 6 **Studie PROSPER – nová indikace „staronového“ léku: enzalutamid v léčbě nemetastatického kastročného rezistentního karcinomu prostaty**
doc. MUDr. Renata Soumarová, Ph.D. Radioterapeutická a onkologická klinika FNKV, 3. LF UK, Praha
- 6 **Sekvenční terapie v léčbě metastatického maligního melanomu**
MUDr. David Šulc Onkologické oddělení Masarykovy nemocnice Ústí nad Labem, Krajská zdravotní, a. s., Ústí nad Labem
- 6 **Precizní medicína a testování NTRK fúzí u maligních nádorů k cílené léčbě pacientů inhibitory TRK**
prof. MUDr. Alena Skálová, CSc. Šiklův ústav patologie LF UK v Plzni a Biopická laboratoř, s. r. o., Plzeň
- 6 **Nový kinázový inhibitor: entrectinib**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 6 **Léčba nádorové bolesti**
MUDr. Jan Lejčko LF UK a Klinika anesteziologie, resuscitace a intenzivní medicíny, Centrum léčby bolesti, FN Plzeň
- 7 **Metylnaltrexon v léčbě opioidy indukované zácpy**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 7 **Nový imunosipping Remune – výsledky multicentrické cross-over studie v ČR**
Pracovní skupina nutriční péče v onkologii (PSNPO):
MUDr. Viktor Maňásek Onkologické oddělení Nemocnice Nový Jičín
MUDr. Štěpán Tuček Masarykův onkologický ústav, Brno
MUDr. Petra Holečková Ústav radiační onkologie Nemocnice Na Bulovce, Praha
prof. MUDr. Samuel Vokurka, Ph.D. Onkologická a radioterapeutická klinika LF UK a FN Plzeň
MUDr. Petr Beneš Interní oddělení Nemocnice Na Homolce, Praha
- 7 **Medicína založená na důkazech: historie, principy a současné výzvy**
prof. MUDr. Lukáš Smolej, Ph.D. IV. interní hematologická klinika, Fakultní nemocnice a LF UK, Hradec Králové
- 7 **Současné doporučení pro léčbu mnohočetného myelomu**
MUDr. Hana Plonková | MUDr. Tomáš Jelínek, Ph.D. | MUDr. Tereza Popková | prof. MUDr. Roman Hájek, CSc.
Klinika hematoonkologie, Fakultní nemocnice Ostrava, Lékařská fakulta Ostravské univerzity, Ostrava

- 8 Management léčby asymptomatického (smoldering) mnohočetného myelomu; strategie „watch and wait“ u monoklonálních gamapatií
MUDr. Denisa Nováková | doc. MUDr. Jakub Radocha, Ph.D. IV. interní hematologická klinika LF UK a FN v Hradci Králové
- 8 Strategie „watch and wait“ u pacientů s chronickou lymfocytární leukémií
MUDr. Dominika ěcsiová | MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové
- 8 Má stále smysl strategie přístupu sledování „watch and wait“ u lymfomů?
MUDr. Alice Sýkorová, Ph.D. | MUDr. David Belada, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové
- 9 Nové léčebné postupy u chronické lymfocytární leukémie
MUDr. Martin Špaček, Ph.D. I. interní klinika – klinika hematologie, VFN a 1. LF UK, Praha
- 9 Léčba chronické myeloidní leukémie – současnost a výhledy
MUDr. Hana Klamová Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha
- 9 Gemtuzumab ozogamicin
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 10 Primární lymfom centrální nervové soustavy – aktuální možnosti léčby
MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FN KV a 3. LF UK, Praha
- 10 Nehodgkinské lymfomy dětí a dospívajících: současné možnosti léčby a výhledy
MUDr. Edita Kabíčková, Ph.D. Klinika dětské hematologie a onkologie 2. LF UK a FN v Motole, Praha
- 10 Jak dál s imunitní trombocytopenií ve světle nejnovějších doporučení
MUDr. Eva Konířová | prof. MUDr. Marek Trněný, CSc. I. interní klinika – klinika hematologie VFN a 1. LF UK, Praha
- 11 Terapeutické využití imunoglobulinů
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 11 Dystymie – psychická porucha s převážně negativním hodnocením všeho prožitého
prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno

Nové možnosti léčby triple negativního karcinomu prsu

MUDr. Miloš Holánek Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- den Brok, W. D. – Speers, C. H. – Gondara, L., et al.: Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. *Breast Cancer Res Treat*, 2017, 161, s. 549–556.
- Bonotto, M. – Gerrata, L. – Poletto, E., et al.: Measures of outcome in metastatic breast cancer: insights from a real-world scenario. *Oncologist*, 2014, 19, s. 608–615.
- Gobbini, E. – Ezzalfani, M. – Dieras, V., et al.: Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. *Eur J Cancer*, 2018, 96, s. 17–24.
- Leehmann, B. D., et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest*, 2011, 121, s. 2750–2767.
- Wang, D.-Y., et al.: Molecular stratification with in triple-negative breast cancer subtypes. *Scientific Reports*, 2019, 9, s. 1–10.
- Tun, N. M., et al.: Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis. *Clinical Genetics*, 2014, 85, s. 43–48.
- Copson, E., et al.: Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. *Lancet Oncol*, 2018, 19, s. 169–180.
- Alli, E., et al.: Enhanced sensitivity to cisplatin and gemcitabine in BRCA1-deficient murine mammary epithelial cells. *BMC Pharmacol*, 2011, 11, s. 7.
- Bhattacharyya, A., et al.: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. *J Biol Chemistry*, 2000, 275, s. 23899–23903.
- Kennedy, R. D., et al.: The role of BRCA1 in the cellular response to chemotherapy. *J National Cancer Inst*, 2004, 96, s. 1659–1668.
- Cortazar, P., et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*, 2014, 384, s. 164–172.
- von Minckwitz, G., et al.: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *J Clin Oncol*, 2012, 30, s. 1796–1804.
- Spring, L. M., et al.: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients. *Cancer Res*, 2019, 79, suppl. 4, abstrakt GS2-03.
- Byrski, T., et al.: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. *J Clin Oncol*, 2009, 28, s. 375–379.
- Byrski, T., et al.: Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. *Breast Cancer Res Treatment*, 2014, 147, s. 401–405.
- Telli, M. L., et al.: Phase II study of gemcitabine, carboplatin, and irinotecan as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. *J Clin Oncol*, 2015, 33, s. 1895.
- Holánek, M., et al.: Effectiveness of neoadjuvant therapy with platinum-based agents for patients with BRCA1 and BRCA2 germline mutations – a retrospective analysis of breast cancer patients treated at MCCI Brno. *Klinická Onkologie*, 2019, 32, suppl. 2, s. 31–35.
- von Minckwitz, G., et al.: Neoadjuvant carboplatin in patient with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 747–756.
- Alba, E., et al.: A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GECAM/2006-03, multicenter study. *Breast Cancer Research Treatment*, 2012, 136, s. 487–493.
- Tung, N., et al.: TBCRC 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). *J Clin Oncol*, 2020, 38, s. 1539–1548.
- Gianni, L., et al.: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. SABCS 2019; Abstract GS3-04. Dostupné z: <https://www.abstractsonline.com/pp8/#!/7946/presentation/1911>, vyhledáno 29. 5. 2020.
- Schmid, P., et al.: Pembrolizumab for early triple-negative breast cancer. *New Eng J Med*, 2020, 382, s. 810–821.
- Robson, M., et al.: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *New Eng J Med*, 2017, 377, s. 523–533.
- Litton, J. K., et al.: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *New Eng J Med*, 2018, 379, s. 753–763.
- Schmid, P., et al.: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *New Eng J Med*, 2018, 379, s. 2108–2121.
- Pascual, J. – Turner, N. C.: Targeting the PI3-kinase pathway in triple-negative breast cancer. *An Oncol*, 2019, 30, s. 1051–1060.
- Baselga, J., et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *New Eng J Med*, 2012, 366, s. 520–529.
- Kim, S.-B., et al.: Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*, 2017, 18, s. 1360–1372.
- Schmid, P., et al.: Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT Trial. *J Clin Oncol*, 2020, 38, s. 423–433.

Adjuvantní léčba HER pozitivního karcinomu prsu

MUDr. Martina Zimovjanová, Ph.D. Onkologická klinika VFN a 1. LF UK, Praha

- Cossetti, R. J. – Tyldesley, S. K. – Speers, C. H., et al.: Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. *J Clin Oncol*, 2015, 33, s. 65–73.
- Lin, N. U. – Winer, E. P.: Brain metastases: the HER2 paradigm. *Clin Cancer Res*, 2007, 13, s. 1648–1655.
- Slamon, D. J. – Godolphin, W. – Jones, L. A., et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science*, 1989, 244, s. 707–712.
- Slamon, D. J. – Leyland-Jones, B. – Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. *New Eng J Med*, 2001, 344, s. 783–792.
- Romond, E. H. – Perez, E. A. – Bryant, J., et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *New Eng J Med*, 2005, 353, s. 1673–1680.
- Slamon, D. – Eiermann, W. – Robert, N., et al.: Breast Cancer International Research Group: Adjuvant trastuzumab in HER-positive breast cancer. *New Eng J Med*, 2011, 365, s. 1273–1283.
- Piccari-Gebhard, M. J. – Procter, M. – Leyland, J. B., et al.: Herceptin adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. *New Eng J Med*, 2005, 353, s. 1659–1672.
- Perez, E. A. – Suman, J. V. – Davidson, N. E., et al.: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. *J Clin Oncol*, 2011, 29, s. 4491–4497.
- Perez, E. A. – Rohmond, E. H. – Suman, V. L., et al.: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. *J Clin Oncol*, 2014, 32, s. 3744–3752.
- Joensuu, H. – Kellokumpu-Lehtinen, P. L. – Bono, P., et al.: FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. *New Eng J Med*, 2006, 354, s. 809–820.
- Pivot, X. – Romieu, G. – Debled, M., et al.: Phare Trial Investigators: 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): A randomised phase 3 trial. *Lancet Oncol*, 2013, 14, s. 741–748.
- Earl, H. M. – Vallier, A. L. – Dunn, J., et al.: Trastuzumab associated cardiac events in Persephone trial. *Br J Cancer*, 2016, 115, s. 1462–1470.
- Moja, L. – Tagliabue, L. – Baldizzi, S., et al.: Trastuzumab containing regimens for early breast cancer. *Cochrane Database Syst Rev*, 2012, 4, CD006243.
- Hurvitz, S. A. – Miller, J. M. – Dichman, R., et al.: Final analysis of phase II 3 arm randomised trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B 07). *Cancer Res*, 2013, 73, suppl, abstrakt 51–02.
- Baselga, J. – Bradbury, I. – Eidtmann, H., et al.: NeoALTO study team: Lapatinib with trastuzumab for HER2 positive early breast cancer (NeoALTO): Randomised open label multicentre phase 3 trial. *Lancet*, 2012, 379, s. 633–640.
- Guarneri, V. – Frassodati, A. – Bittini, A., et al.: Preoperative chemotherapy plus trastuzumab, lapatinib or both in human epidermal growth factor receptor 2 positive operable breast cancer. Results of the randomised phase II CHER-LOB study. *J Clin Oncol*, 2012, 30, s. 1989–1995.
- Schneeweiss, A. – Chia, S. – Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline containing and anthracycline-free chemotherapy regimens in patients with HER2 positive early breast cancer: Randomised phase 2 cardiac safety study (TRYPHAENA). *Ann Oncol*, 2013, 2004, s. 2278–2284.
- Gianni, L. – Pienkowski, T. – Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced inflammatory or early HER2 positive breast cancer (NeoSphere): Randomised multicentre open label phase II trial. *Lancet Oncol*, 2012, 13, s. 25–32.
- Loibl, S. – Majewski, I. – Guarneri, V., et al.: PIK3CA mutations are associated with reduced pathological complete response rate in primary HER2 positive breast cancer: Pool analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. *An Oncol*, 2016, 27, s. 1519–1525.
- Solinas, C. – Cappi, M. – Lambertini, M., et al.: Tumor infiltrating lymphocytes in patients with HER2 positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomised controlled trials. *Cancer Treat Rev*, 2017, 57, s. 8–15.
- Von Minckwitz, G. – Huang, C. S. – Mano, M. S., et al.: KATHERINE investigators: Trastuzumab emtansine for residual invasive HER2 positive breast cancer. *New Eng J Med*, 2019, 380, s. 617–628.
- Murthy, R. K. – Loi, S. – Okines, A., et al.: Tucatinib, trastuzumab and capecitabine for HER2 positive metastatic breast cancer. *New Eng J Med*, 2020, 382, s. 597–609.
- Von Minckwitz, G. – Procter, M. – De Azambuja, E., et al.: APHINITY steering committee and investigators: Adjuvant pertuzumab and trastuzumab in early HER2 positive breast cancer. *New Eng J Med*, 2017, 377, s. 122–131.
- Chan, A. – Delaloge, S. – Holmes, F. A., et al.: ExteNET study group: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2 positive breast cancer (ExteNET): Multicentre randomised double blind placebo controlled phase III trial. *Lancet Oncol*, 2016, 17, s. 367–377.
- Tolaney, S. M. – Barry, W. T. – Dang, C. T., et al.: Adjuvant paclitaxel and trastuzumab for node negative HER2 positive breast cancer. *New Eng J Med*, 2015, 372, s. 134–141.

Algoritmus léčby metastatického karcinomu ledviny v roce 2020

doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- Dušek, L. – Mužík, J. – Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita. Dostupné z: <http://www.svod.cz>. 2005, vyhledáno 3. 3. 2019.
- Ljungberg, B. – Bensalah, K. – Canfield, S., et al.: EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol*, 2015, 67, s. 913–924.
- Mejean, A. – Ravaud, A. – Thezenas, S., et al.: Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. *New Eng J Med*, 2018, 379, s. 417–427.
- Zhoubný novotvar ledviny (C64). *Modrá kniha České onkologické společnosti*. 26. aktualizace. Masarykův Onkologický Ústav, Brno. Platnost od 1. 3. 2020; 2020.
- Motzer, R. J. – Tannir, N. M. – McDermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *New Eng J Med*, 2018, 378, s. 1277–1290.
- Hudes, G. – Carducci, M. – Tomczak, P., et al.: Temeirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *New Eng J Med*, 2007, 356, s. 2271–2281.
- Motzer, R. J. – Escudier, B. – McDermott, D. F., et al.: Nivolumab versus everolimus in advanced renal-cell carcinoma. *New Eng J Med*. 2015, 373, s. 1803–1813.
- Choueiri, T. K. – Escudier, B. – Powles, T., et al.: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2016, 17, s. 917–927.

Možnosti imuno-onkologické léčby v terapii malobuněčných karcinomů plic

prof. MUDr. Miloš Pešek, CSc. Klinika pneumologie a ftizeologie, FN a LF UK Plzeň

- Rudin, C. – Shen, L. – Pietanza, M. C.: KEYNOTE-604: Phase 3 randomized, double-blind trial of pembrolizumab/placebo plus etoposide/ platinum for extensive-stage-SCLC. *J Thorac Oncol*, 2017, 12, P2.04-007, DOI: <https://doi.org/10.1016/j.jtho.2017.11.020>.
- Small Cell Lung Cancer (SCLC) Highlights of prescribing informatik. These highlights do not include all the information needed to use KEYTRUDA safely and effectively. See full prescribing information for KEYTRUDA – for the treatment of patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.1 (1.3) Reference ID: 4544325, s. 1–85.
- Paz-Ares, L. – Dvorkin, M. – Chen, Y., et al.; for the CASPIAN investigators: Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*, 2019, 394, s. 1929–1939.
- Senan, S. – Okamoto, I. – Lee, G.-W., et al.: Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small-cell lung cancer: The ADRIATIC Study. *Clinical Lung Cancer*, 2020, 21, s. e84–e88.
- Calles, A. – Aguado, G. – Sandoval, C., et al.: The role of immunotherapy in small cell lung cancer. *Clin Transl Oncol*, 2019, 21, s. 961–976.
- George, J. – Lim, J. S. – Jang, S. J., et al.: Comprehensive genomic profiles of small cell lung cancer. *Nature*, 2015, 524, s. 47–53.
- Rudin, C. M. – Poirier, J. T. – Byers, L. A., et al.: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data NATuRe RevleWS. *Cancer*, 2019, 19, s. 289–297.
- Hellmann, M. D. – Callahan, M. K. – Awad, M. M., et al.: Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. *Cancer Cell*, 2018, 33, s. 1–9.
- Poirier, J. T. – George, J. – Owonikoko, T. K., et al.: New approaches to SCLC therapy: from the laboratory to the clinic. *J Thorac Oncol*, 2020, 15, s. 520–540.
- Reck, M. – Bondarenko, I. – Luft, A., et al.: Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. *Ann Oncol*, 2013, 24, s. 75–83.
- Arriola, E. – Wheeler, M. – Galea, I., et al.: Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. *J Thorac Oncol*, 2016, 11, s. 1511–1521.
- Reck, M. – Luft, A. – Szczesna, A., et al.: Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. *J Clin Oncol*, 2016, 34, s. 3740–3748.
- Antonia, S. J. – Lopez-Martin, J. A. – Bendell, J., et al.: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol*, 2016, 17, s. 883–895.
- Hellmann, M. D. – Ott, P. A. – Zugazogaitia, J., et al.: Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate 032. *J Clin Oncol*, 2017, 35, 15 suppl., s. 8503.
- National Comprehensive Cancer Network. Small Cell Lung Cancer (Version 2.2018). Dostupné z: https://www.nccn.org/professionals/physi/cian_gls/pdf/sclcl.pdf, vyhledáno 15. 6. 2018.
- Ott, P. A. – Elez, E. – Hiret, S., et al.: Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 Study. *J Clin Oncol*, 2017, 35, s. 3823–3829.
- Chung, H. C. – Lopez-Martin, J. A. – Kao, S. C.-H., et al.: Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. *J Clin Oncol*, 2018, 36, suppl. 15, s. 8506.
- Gadgeel, S. M. – Pennell, N. A. – Fidler, M. J., et al.: Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). *J Thorac Oncol*, 2018, 13, s. 1393–1399.
- Rudin, C. M. – Shen, L. – Pietanza, M. C.: KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC). *An Oncol*, 2017, 28, suppl. 5, s. v539–v542.
- Sequist, L. V. – Chiang, A. – Gilbert, J., et al.: Clinical activity, safety and predictive bio-markers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC). *An Oncol*, 2016, 27, s. 493–496.
- Pujol, J. L. – Greillier, L. – Audigier, V. C., et al.: A randomized non-comparative phase II study of anti-PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial. *J Thorac Oncol*, 2019, 14, s. 903–913.
- Horn, L. – Mansfield, A. S. – Szczesna, A., et al.: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med*, 2018, 379, s. 2220–2229.
- Pawel, J. V. – Vynnychenko, I. – Jiang, H., et al.: A phase II, open-label, multi-arm study of novel combinations of immunotherapies or DDR inhibitors in platinum-refractory, extensive disease small-cell lung cancer (ED-SCLC): BALTIC. *J Clin Oncol*, 2017, suppl. 15, DOI: 10.1200/JCO.2017.35.15_suppl.TPS8585.
- Paz-Ares, L. – Jiang, H. – Huang, Y., et al.: CASPIAN: phase 3 study of first-line durvalumab ± ireremelumab + platinum-based chemotherapy vs chemotherapy alone in ED-SCLC. *J Thorac Oncol*, 2017, 12, s. S2398.
- George, J. – Lim, J. S. – Jang, S. J., et al.: Comprehensive genomic profiles of small cell lung cancer. *Nature*, 2015, 524, s. 47–67.
- Liu, S. – Mansfield, A. – Szczesna, A., et al.: PL02.07 IMPower 133: primary PFS, OS and safety in a PH1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC. *J Thoracic Oncol*, 2018, 13, s. S185–S186.
- Zarogoulidis, K. – Ziogas, E. – Papagiannis, A., et al.: Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. *Lung Cancer*, 1996, 15, s. 197–205.

Virtuální konference ASCO 2020 a léčba karcinomu plic

MUDr. Leona Koubková Pneumologická klinika UK 2 LF a FN v Motole, Praha

- Gainor, J. F. – Curigliano, G. – Kim, D.-W., et al.: Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2020, 38, suppl., s. 9515–9515.
- Peters, S. – Mok, T. S. K. – Gadgeel, S. M., et al.: Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. *J Clin Oncol*, 2020, 38, suppl., s. 9518–9518.
- Wolf, J. – Overbeck, T. R. – Han, J. I., et al.: Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. *J Clin Oncol*, 2020, 38, suppl., s. 9509–9509.
- Camidge, D. R. – Janku, F. – Martinez-Bueno, A., et al.: Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METamp/Ex14). *J Clin Oncol*, 2020, 38, suppl., s. 9510–9510.
- Smit, E. F. – Nakagawa, K. – Nagasaka, M., et al.: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. *J Clin Oncol*, 2020, 38, suppl., s. 9504–9504.
- Maemondo, M. – Fukuhara, T. – Saito, H., et al.: NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. *J Clin Oncol*, 2020, 38, suppl., s. 9506–9506.
- Wang, X. – Zeng, M.: First-line tyrosinekinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332). *J Clin Oncol*, 2020, 38, suppl., s. 9508–9508.
- Rotow, J. K. – Botelho Costa, D. – Paweletz, C. P., et al.: Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2020, 38, suppl., s. 9507–9507.
- Herbst, R. S. – Tsuboi, M. – John, T., et al.: Osimertinib as adjuvant therapy in patients with stage IB-IIIa EGFR mutation positive NSCLC after complete tumor resection: ADAURA. ASCO20 Virtual Scientific Program. Abstract LBA5. *J Clin Oncol*, 2020, 38, suppl., DOI: 10.1200/JCO.2020.38.18_suppl.LBA5.
- Rodriguez-Abreu, D. – Johnson, M. L. – Hussein, M. A., et al.: Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). *J Clin Oncol*, 2020, 38, suppl., s. 9503–9503.
- Ramalingam, S. S. – Ciuleanu, T. E. – Pluzanski, A., et al.: Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. *J Clin Oncol*, 2020, 38, suppl., s. 9500–9500.
- Reck, M. – Ciuleanu, T. E. – Cobo Dols, M., et al.: Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. *J Clin Oncol*, 2020 38, suppl., s. 9501–9501.
- Leal, T. – Wang, Y. – Dowlati, A., et al.: Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. *J Clin Oncol*, 2020, 38, suppl., s. 9000–9000.
- Jabbour, S. K. – Lee, K. H. – Frost, N., et al.: Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. *J Clin Oncol*, 2020, 38, suppl., s. 9008–9008.
- Garassino, M. Ch. – Gadgeel, S. M. – Rodriguez-Abreu, D., et al.: Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC. *J Clin Oncol*, 2020, 38, suppl., s. 9521–9521.
- Rudin, C. M. – Awad, M. M. – Navarro, A., et al.: KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). *J Clin Oncol*, 2020, 38, suppl., s. 9001–9001.
- Paz-Ares, L. – Dvorkin, M. – Chen, Y., et al.: Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): updated results from the phase III CASPIAN study. *J Clin Oncol*, 2020, 38, suppl., s. 9002–9002.

Durvalumab po chemoradioterapii nemalobuněčného plicního karcinomu – mění se paradigma konsolidační léčby

MUDr. Gabriela Krákorová, Ph.D. Klinika pneumologie a ftizeologie, FN a LF UK, Plzeň

MUDr. Radovan Vojtíšek, Ph.D. Onkologická a radioterapeutická klinika, FN a LF UK, Plzeň

- Skříčková, J. – Pešek, M. – Koleček, V., et al.: Klinický standard komplexní péče o pacienty s bronchogenním nemalobuněčným karcinomem plic. Dostupné z: www.pneumologie.cz, vyhledáno 1. 5. 2020.
- Scorsetti, M. – Navarria, P. – Mancosu, P., et al.: Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc. *Radiat Oncol*, 2010, 5, s. 94.
- American Cancer Society. NSCLC survival rates by stage. Dostupné z: <https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html>, vyhledáno 1. 5. 2020.
- Cancer Research UK. Dostupné z: <http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer/incidence#heading=Three>, vyhledáno 1. 5. 2020.
- Postmus, P. E., et al.: Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2017, 28, suppl. 4, s. iv1–iv21.
- Bradley, J. D. – Paulus, R. – Komaki, R., et al.: Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients

- with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncol*, 2015, 16, s. 187–199.
- 7 Tsujino, K., et al.: Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer?: A pooled analysis of the literature. *J Thorac Oncol*, 2013, 8, s. 1181–1189.
 - 8 Postmus, P. E. – Kerr, K. M. – Oudkerk, M., et al.: ESMO Guidelines Committee: Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2017, 28, suppl. 4, s. iv1–iv21.
 - 9 Silvestri, G. A. – Gould, M. K. – Margolis, M. L., et al.: American College of Chest Physicians: Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). *Chest*, 2007, 132, suppl. 3, s. 178S–201S.
 - 10 Yu, B. – Zhu, X. – Liang, Z., et al.: Clinical usefulness of 18F-FDG PET/CT for the detection of distant metastases in patients with non-small cell lung cancer at initial staging: a meta-analysis. *Cancer Manag Res*, 2018, 10, s. 1859–1864.
 - 11 Brink, I. – Schumacher, T. – Mix, M., et al.: Impact of [18F] FDG-PET on the primary staging of small-cell lung cancer. *Eur J Nucl Med Mol Imag*, 2004, 31, s. 1614–1620.
 - 12 van Tinteren, H. – Hoekstra, O. S. – Smit, E. F., et al.: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. *Lancet*, 2002, 359, s. 1388–1393.
 - 13 Fischer, B. – Lassen, U. – Mortensen, J., et al.: Preoperative staging of lung cancer with combined PET-CT. *N Engl J Med*, 2009, 361, s. 32–39.
 - 14 Vella, M. – Meyer, C. S. – Zhang, N., et al.: Association of receipt of positron emission tomography – computed tomography with non-small cell lung cancer mortality in the Veterans Affairs health care system. *JAMA Netw Open*, 2019, 2, s. e1915828.
 - 15 Aupérin, A. – LePéchoux, C. – Rolland, E., et al.: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small cell lung cancer. *J Clin Oncol*, 2010, 28, s. 2181–2190.
 - 16 Schmidt-Hansen, M. – Baldwin, D. R. – Hasler, E., et al.: PET-CT for assessing mediastinal lymphnode involvement in patients with suspected resectable non-small cell lung cancer. *Cochrane Database Syst Rev*, 2014, CD009519.
 - 17 Vojtišek, R. – Mužik, J. – Šlampa, P., et al.: The impact of PET/CT scanning on the size of target volumes, radiation exposure of organs at risk, TCP and NTCP, in the radiotherapy planning of non-small cell lung cancer. *Rep Pract Oncol Radiother*, 2014, 19, s. 182–190.
 - 18 Bradley, J. D. – Paulus, R. – Komaki, R., et al.: Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. *Lancet Oncol*, 2015, 16, s. 187–199.
 - 19 De Ruysscher, D. – Favre-Finn, C. – Moeller, D., et al.: Lung Group and the Radiation Oncology Group of the European Organization for Research and Treatment of Cancer (EORTC): European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. *Radiother Oncol*, 2017, 124, s. 1–10.
 - 20 Santana-Davila, R. – Devisetty, K. – Szabo, A., et al.: Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration Data. *J Clin Oncol*, 2015, 33, s. 567–574.
 - 21 Glatzer, M. – Elicin, O. – Ramella, S., et al.: Radio(chemo)therapy in locally advanced non-small cell lung cancer. *Eur Respir Rev*, 2016, 25, s. 65–70.
 - 22 Zatloukal, P. – Zemanova, M. – Havel, L., et al.: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. *Lung Cancer*, 2004, 46, s. 87–98.
 - 23 Senan, S. – Brade, A. – Wang, L. H., et al.: PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. *J Clin Oncol*, 2016, 34, s. 953–962.
 - 24 Santana-Davila, R. – Devisetty, K. – Szabo, A., et al.: Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: An analysis of Veterans Health Administration Data. *J Clin Oncol*, 2015, 33, s. 567–574.
 - 25 Vokes, E. E. – Herndon, J. E. 2nd – Kelley, M. J., et al.: Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. *J Clin Oncol*, 2007, 25, s. 1698–1704.
 - 26 Hanna, N. – Neubauer, M. – Yiannoutsos, C., et al.: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. *J Clin Oncol*, 2008, 26, s. 5755–5760.
 - 27 Lilienbaum, R. – Samuels, M. – Wang, X.: A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III non-small cell lung cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). *J Thorac Oncol*, 2015, 10, s. 143–147.
 - 28 Kelly, K. – Chansky, K. – Gaspar, L. E., et al.: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. *J Clin Oncol*, 2008, 26, s. 2450–2456.
 - 29 Gore, E. M. – Bae, K. – Wong, S. J., et al.: Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of Radiation Therapy Oncology Group study RTOG 0214. *J Clin Oncol*, 2011, 29, s. 272–278.
 - 30 Antonia, S. J., et al.: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med*, 2017, 377, s. 1919–1929.
 - 31 Antonia, S. J., et al.: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *N Engl J Med*, 2018, 379, s. 2342–2350.

Atezolizumab a chemoterapie v první linii léčby extenzivního malobuněčného karcinomu plic – studie IMpower133

MUDr. Libor Havel Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha

- 1 Horn, L. – Mansfield, A. S. – Szczesna, A., et al.: First line atezolizumab plus chemotherapy in extensive stage small-cell lung cancer. *N Engl J Med*, 2018, 379, s. 2220–2229.

Využitie amfotericínu B vo forme lipidového komplexu v liečbe invazívnej aspergilózy – kazuistika

MUDr. Ladislav Sopko, PhD. Klinika Hematológie a transfúziológie, LFUK, SZU a Univerzitná nemocnica, Bratislava

- 1 Tissot, F. – Agrawal, S. – Pagano, L., et al.: ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. *Haematologica*, 2017, 102, s. 433.
- 2 Patterson, T. F. – Thompson, G. R. 3rd. – Denning, D. W., et al.: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*, 2016, 63, s. e1.
- 3 Ullmann, A. J. – Aguado, J. M. – Arikan-Akdagli, S., et al.: Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. *Clin Microbiol Infect*, 2018, 24, suppl. 1, s. e1.
- 4 Marr, K. A. – Schlamm, H. T. – Herbrecht, R., et al.: Combination antifungal therapy for invasive aspergillosis: a randomized trial. *Ann Intern Med*, 2015, 162, s. 81.
- 5 Imhof, A. – Balajee, S. A. – Fredricks, D. N., et al.: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. *Clin Infect Dis*, 2004, 39, s. 743.

Liečba invazívnej pľúcnej mykotickej infekcie v praxi u onkohematologického pacienta – kazuistika

MUDr. Tomáš Guman, PhD. Klinika hematológie a onkohematológie (KHaOH), Univerzitná nemocnica L. Pasteura a LF UPJŠ, Košice

- 1 Kontoyiannis, D. P. – Marr, K. A. – Park, B. J., et al.: Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clin Infect Dis*, 2010, 50, s. 1091–1100.
- 2 Ráčil, Z. – Kocmanová, I. – Wagnerová, B., et al.: Časná diagnostika invazívnych mykotických infekcií u hematologických nemocných pomocou sérologických metód. *Vnitřní lékař*, 2007, 53, s. 645–654.
- 3 Haber, J. – Mallátová, N. – Kocmanová, I.: Invazívni mykózy. *Epidemiologie, diagnostika, léčba*. Pfizer, 2007.
- 4 Patterson, T. F. – White, W. R. – White, M., et al.: Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. *Medicine*, 2000, 79, s. 250–260.
- 5 Pagano, L. – Akova, M. – Dimopoulos, G., et al.: Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. *Antimicrob Chemother*, 2011, 66, suppl. 1, s. i5–i14.
- 6 Pagano, L. – Caira, M. – Candoni, A., et al.: The epidemiology of fungal infections in patients with hematologic malignancies: the SEIF-EM-2004 study. *Haematologica*, 2006, 91, s. 1068–1075.
- 7 Cornillet, A. – Camus, C. – Nimubona, S., et al.: Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. *Clin Infect Dis*, 2006, 43, s. 577–584.
- 8 Herbrecht, R. – Denning, D. W. – Patterson, T. F., et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med*, 2002, 347, s. 408–415.
- 9 Tissot, F. – Agrawal, S. – Pagano, L., et al.: ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. *Haematologica*, 2017, 102, s. 433–444.
- 10 Resendiz Sharpe, A. – Lagrou, K. – Meis, J. F., et al.: Triazole resistance surveillance in *Aspergillus fumigatus*. *Med Mycol*, 2018, 56, suppl. 1, s. 83–92.

Studie PROSPER – nová indikace „staronového“ léku: enzalutamid v léčbě nemetastatického kastročně rezistentního karcinomu prostaty

doc. MUDr. Renata Soumarová, Ph.D. Radioterapeutická a onkologická klinika FNKV, 3. LF UK, Praha

- Hussain, M. – Fizazi, K. – Saad, F., et al.: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2018, 378, s. 2465–2474.
- Sternberg, C. N. – Fizazi, K. – Saad, F., et al.: Enzalutamid and survival in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*, 2020, 382, s. 2197–2206.
- Scher, H. I. – Fizazi, K. – Saad, F., et al.: Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med*, 2012, 367, s. 1187–1197.
- Fizazi, K. – Scher, H. I. – Miller, K., et al.: Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. *Lancet Oncol*, 2014, 15, s. 1147–1156.
- Beer, T. M. – Armstrong, A. J. – Rathkopf, D., et al.: Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. *Eur Urol*, 2017, 71, s. 151–154.
- Attard, G. – Saad, F. – Tombal, B., et al.: Health-related quality of life (HRQoL) deterioration and pain progression in men with nonmetastatic castration-resistant prostate cancer (MO CRPC): results from the PROSPER study. *J Clin Oncol*, 2018, 36, s. 5010.
- de Bono, J. S. – Scher, H. I. – Montgomery, R. B., et al.: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res*, 2008, 14, s. 6302–6309.
- Thalgott, M. – Rack, B. – Maurer, T., et al.: Detection of circulating tumor cells in different stages of prostate cancer. *J Cancer Res Clin Oncol*, 2013, 139, s. 755–763.

Sekvenční terapie v léčbě metastatického maligního melanomu

MUDr. David Šulc Onkologické oddělení Masarykovy nemocnice Ústí nad Labem, Krajská zdravotní, a. s., Ústí nad Labem

- Robert, C. – Ribas, A. – Schachter, J., et al.: Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncol*, 2019, 20, s. 1239–1251.
- Larkin, J. – Chiarion-Sileni, V. – Gonzalez, R., et al.: Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med*, 2019, 381, s. 1535–1546.
- Robert, C. – Grob, J. J. – Stroyakovskiy, D. – Karaszewska, B., et al.: Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. *N Engl J Med*, 2019, 381, s. 626–636.
- Giunta, E. F. – De Falco, V. – Napolitano, S., et al.: Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. *Ther Adv Med Oncol*, leden 2020.

Precizní medicína a testování NTRK fúzí u maligních nádorů k cílené léčbě pacientů inhibitory TRK

prof. MUDr. Alena Skálová, CSc. Šiklův ústav patologie LF UK v Plzni a Biopoptická laboratoř, s. r. o., Plzeň

- Pulciani, S. – Santos, E. – Lauver, A. V., et al.: Oncogenes in solid human tumours. *Nature*, 1982, 300, s. 539–542.
- Amatu, A. – Sartore-Bianchi, A. – Siena, S.: NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. *ESMO Open*, 2016, 1, s. e000023.
- Drilon, A. – Laetsch, W. T. – Kummar, S., et al.: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *NEJM*, 2018, 378, s. 731–739.
- Scott, L. J.: Larotrectinib: first global approval. *Drugs*, 2019, 79, s. 201–206.
- Kummar, S. – Lassen, U. N.: TRK inhibition: a new tumor-agnostic treatment strategy. *Targeted Oncology*, 2018, 13, s. 545–556.
- Skálová, A. – Vaněček, T. – Šíma, R., et al.: Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. *Am J Surg Pathol*, 2010, 34, s. 599–608.
- Church, A. J. – Calicchio, M. L. – Nardi, V., et al.: Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. *Mod Pathol*, 2018, 31, s. 463–473.
- Leeman-Neill, R. J. – Kelly, L. M. – Liu, P., et al.: ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. *Cancer*, 2014, 120, s. 799–807.
- Prasad, M. L. – Vyas, M. – Horne, M. J., et al.: NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. *Cancer*, 2016, 122, s. 1097–1107.
- Wiesner, T. – He, J. – Yelensky, R., et al.: Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. *Nat Commun*, 2014, 5, s. 3116.
- Kim, J. – Lee, Y. – Cho, H. J., et al.: NTRK1 fusion in glioblastoma multiforme. *PLoS One*, 2014, 9, s. e91940.
- Shi, E. – Chmeielecki, J. – Tang, C. M., et al.: FGFR1 and NTRK3 actionable alterations in „Wild-Type“ gastrointestinal stromal tumors. *J Transl Med*, 2016, 14, s. 339.
- Chiang, S. – Cotzia, P. – Hyman, D. M., et al.: NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma. *Am J Surg Pathol*, 2018, 42, s. 791–798.
- Michal, M. – Hájková, V. – Skálová, A., et al.: STRN-NTRK3-rearranged mesenchymal tumor of the uterus: expanding the morphologic spectrum of tumors with NTRK fusions. *Am J Surg Pathol*, 2019, 43, s. 1152–1154.
- Suurmeijer, A. J. – Dickson, B. C. – Swanson, D., et al.: The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements. *Genes Chromosomes Cancer*, 2019, 58, s. 739–746.
- Yamazaki, F. – Nakatani, F. – Asano, N., et al.: Novel NTRK3 fusions in fibrosarcomas of adults. *Am J Surg Pathol*, 2019, 43, s. 523–530.
- Lasota, J. – Chlopek, M. – Lamoureaux, J., et al.: Colonic adenocarcinomas harboring NTRK fusion genes: a clinicopathologic and molecular genetic study of 16 cases and review of the literature. *Am J Surg Pathol*, 2020, 44, s. 163–173.
- Solomon, J. P. – Linkov, I. – Rosado, A., et al.: NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. *Mod Pathol*, 2020, 33, s. 38–46.
- Gatalica, Z. – Xiu, J. – Swensen, J., et al.: Molecular characterization of cancers with NTRK gene fusions. *Mod Pathol*, 2019, 32, s. 147–153.

Nový kinázový inhibitor: entrectinib

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- Rolfo, C. – Ruiz, R. – Giovannetti, E., et al.: Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. *Expert Opin Investig Drugs*, 2015, 24, s. 1493–1500.
- Product Monograph. Rozlytrek. FDA 2019.
- Ardini, E. – Menichincheri, M. – Banfi, P., et al.: Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. *Mol Cancer Ther*, 2016, 15, s. 628–639.
- Cook, P. J. – Thomas, R. – Kannan, R., et al.: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. *Nat Commun*, 2017, 8, s. 15987.
- Nishiyama, A. – Yamada, T. – Kita, K., et al.: Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model. *Clin Cancer Res*, 2018, 24, s. 2357–2369.
- Drilon, A. – Siena, S. – Dziadziuszko, R., et al.: Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. *Lancet Oncol*, 2020, 21, s. 261–270.
- Drilon, A. – Siena, S. – Ou, S. I., et al.: Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase 1 trials (ALKA-372-001 and STARTRK-1). *Cancer Discov*, 2017, 7, s. 400–409.
- Farago, A. F. – Le, L. P. – Zheng, Z., et al.: Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. *J Thorac Oncol*, 2015, 10, s. 1670–1674.
- Doebele, R. C. – Drilon, A. – Paz-Ares, L., et al.: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol*, 2020, 21, s. 271–282.
- Rolfo, C. – de Braud, F. – Doebele, R. C., et al.: Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) solid tumours: an updated integrated analysis. ASCO, 2020, P335.
- Desai, A. V. – Robinson, G. W. – Basu, E. M., et al.: Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors. ASCO, 2020, dostupné z: <https://bit.ly/3ft45c8>.
- Vagiannis, D. – Yu, Z. – Novotna, E., et al.: Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme. *Biochem Pharmacol*, 2020, 178, s. 114061.

Léčba nádorové bolesti

MUDr. Jan Lejčko LF UK a Klinika anesteziologie, resuscitace a intenzivní medicíny, Centrum léčby bolesti, FN Plzeň

- WHO. *Cancer pain relief: report of a WHO expert committee*. 2. vydání, WHO, 1996.
- Kolektiv autorů: Metodické pokyny pro farmakoterapii bolesti. *Bolest*, 2009, suppl. 2.
- Rokyta, R. – Kršák, M. – Kozák, J. *Bolest*. Tigris, Praha, 2012.
- Higginson, I. J. – Hearn, J. – Addington-Hall, J., In: Sykes, N. – Fallon, M. T. – Patt, R. B.: *Clinical Pain Management-Cancer Pain*. London, Arnold, 2003, s. 21–32.
- Watson, C. P. – Moulin, D. – Watt-Watson, J. et al.: Controlled-release oxycodone relieves neuropathic pain: a randomised controlled trial in painful diabetic neuropathy. *Pain*, 2003, 105, s. 71–78.
- Ahmedzai, S. – Brooks, D.: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. *J Pain Symptom Manage*, 1997, 13, s. 254–261.
- Portenoy, R. K., et al.: Oral transmucosal fentanyl (OTFC) for the treatment of breakthrough pain in cancer patients. *Pain*, 1999, 79, s. 303–312.

Metylnaltrexon v léčbě opioidy indukované zácpy

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 **Kalso, E. – Edwards, J. E. – Moore, R. A. – McQuay, H. J.**: Opioids in chronic non-cancer pain: systematic review of efficacy and safety. *Pain*, 2004, 112, s. 372–380.
- 2 **Bell, T. J. – Panchal, S. J. – Miskowski, C., et al.**: The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). *Pain Med*, 2009, 10, s. 35–42.
- 3 **Manara, L. – Bianchi, G. – Ferretti, P., et al.**: Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. *J Pharmacol Exp Ther*, 1986, 237, s. 945–949.
- 4 **Brown, D. R. – Goldberg, L. I.**: The use of quaternary narcotic antagonists in opiate research. *Neuropharmacology*, 1985, 24, s. 181–191.
- 5 **Chandrasekaran, A. – Tong, Z. – Li, H., et al.**: Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans. *Drug Metab Dispos*, 2010, 38, s. 606–616.
- 6 **Yuan, C. S. – Foss, J. F. – Osinski, J., et al.**: The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. *Clin Pharmacol Ther*, 1997, 61, s. 467–475.
- 7 **Mozaffari, S. – Nikfar, S. – Abdollahi, M.**: Methylnaltrexone bromide for the treatment of opioid-induced constipation. *Expert Opin Pharmacother*, 2018, 19, s. 1127–1135.
- 8 **Foss, J. F. – O'Connor, M. F. – Yuan, C. S., et al.**: Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study. *J Clin Pharmacol*, 1997, 37, s. 25–30.
- 9 **Sobolevsky, T. – Kucherova, Y. – Ahrens, B.**: Identification of oxymorphone as decomposition product of the permitted drug methylnaltrexone. *Drug Test Anal*, 2018, 10, s. 892–895.
- 10 **Yuan, C. S. – Doshan, H. – Charney, M. R., et al.**: Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. *J Clin Pharmacol*, 2005, 45, s. 538–546.
- 11 **Thomas, J. – Karver, S. – Cooney, G. A., et al.**: Methylnaltrexone for opioid-induced constipation in advanced illness. *N Engl J Med*, 2008, 358, s. 2332–2343.
- 12 **Mehta, N. – O'Connell, K. – Giambone, G. P., et al.**: Efficacy of methylnaltrexone for the treatment of opioid-induced constipation: a meta-analysis and systematic review. *Postgrad Med*, 2016, 128, s. 282–289.
- 13 **Brocklebank, J. – Miller, E. J. – Fingas, S.**: Naloxegol rescue with methylnaltrexone highly effective. *BMJ Support Palliat Care*, 2020, 10, s. 316–317.
- 14 **Chamberlain, B. H. – Rhiner, M. – Slatkin, N. E., et al.**: Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer. *Pain Manag*, 2020, 10, s. 73–84.
- 15 **Michna, E. – Blonsky, E. R. – Schulman, S., et al.**: Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. *J Pain*, 2011, 12, s. 554–562.
- 16 **Michna, E. – Weil, A. J. – Duerden, M., et al.**: Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis. *Pain Med*, 2011, 12, s. 1223–1230.
- 17 **Slatkin, N. – Thomas, J. – Lipman, A. G., et al.**: Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. *J Support Oncol*, 2009, 7, s. 39–46.
- 18 **Janku, F. – Johnson, L. K. – Karp, D. D., et al.**: Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. *Ann Oncol*, 2016, 27, s. 2032–2038.
- 19 **Franchi, F. – Rollini, F. – Park, Y., et al.**: Effects of methylnaltrexone on ticagrelor-induced antiplatelet effects in coronary artery disease patients treated with morphine. *JACC Cardiovasc Interv*, 2019, 12, s. 1538–1549.

Nový imunosipping Remune – výsledky multicentrické cross-over studie v ČR

Pracovní skupina nutriční péče v onkologii (PSNPO):

MUDr. Viktor Maňásek Onkologické oddělení Nemocnice Nový Jičín

MUDr. Štěpán Tuček Masarykův onkologický ústav, Brno

MUDr. Petra Holečková Ústav radiační onkologie Nemocnice Na Bulovce, Praha

prof. MUDr. Samuel Vokurka, Ph.D. Onkologická a radioterapeutická klinika LF UK a FN Plzeň

MUDr. Petr Beneš Interní oddělení Nemocnice Na Homolce, Praha

- 1 **Falewee, M. N. – Schilf, A. – Boufflers, E., et al.**: Reduced infections with perioperative immunonutrition in head and neck cancer: exploratory results of a multicenter, prospective, randomized, double-blind study. *Clinical Nutrition*, 2014, 33, s. 776–784.
- 2 **de van der Schueren, M. A. E. – Laviano, A. – Blanchard, H., et al.**: Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. *An Oncol*, 2018, 29, s. 1141–1153.

Medicína založená na důkazech: historie, principy a současné výzvy

prof. MUDr. Lukáš Smolej, Ph.D. IV. interní hematologická klinika, Fakultní nemocnice a LF UK, Hradec Králové

- 1 **Sackett, D. L. – Rosenberg, W. M. – Gray, J. A., et al.**: Evidence based-medicine: what it is and what it isn't. *BMJ*, 1996, 312, s. 71–72.
- 2 **van Helmont, J. B.**: Van Helmont's works containing his most excellent philosophy, physick, chirurgery, anatomy; wherein the philosophy of the schools is examined, their errors refuted, and the whole body of physick reformed and rectified: being a new rise and progresse of philosophy and medicine, for the cure of diseases, and lengthening of life. Londýn, Loyd, 1664, s. 1577–1644. Dostupné z: <https://quod.lib.umich.edu/e/eebo/A43285.0001.001?view=toc>, vyhledáno 20. 8. 2020.
- 3 **Lind, J.**: *A Treatise on the Scurvy*. In three parts, containing an inquiry into the nature, causes, an cure, of that disease, together with a critical and chronological view of what has been published on the subject. Londýn, Millar, 1753.
- 4 **Flint, A.**: Clinical report on hydro-peritoneum based on an analysis of forty-six cases. *Am J Med Sci*, 1863, 45, s. 306–339.
- 5 **Fisher, R. A. – Mackenzie, W. A.**: Studies in crop variation, II. The manurial response of different potato varieties. *J Agric Sci*, 1923, 12, s. 311–320.
- 6 **Amberson, J. R. – McMahon, B. T. – Pinner, M.**: A clinical trial of sanocrysin in pulmonary tuberculosis. *Am Rev Tuberculosis*, 1931, 24, s. 401–435.
- 7 **Medical Research Council**: Streptomycin treatment of pulmonary tuberculosis. *Br Med J*, 1948, 2, s. 769–782.
- 8 **Cochrane, A. L.**: Effectiveness and efficiency: Random reflections on health services. The Nuffield Provincial Hospitals Trust; 1972, s. 92. Dostupné z: <https://www.nuffieldtrust.org.uk/files/2017-01/effectiveness-and-efficiency-web-final.pdf>, vyhledáno 20. 8. 2020.
- 9 Dostupné z: www.cochrane.org, vyhledáno 3. 8. 2020.
- 10 **Greenhalgh, T.**: How to Read a Paper. The basic of evidence based medicine. Londýn, BMJ Books, Publishing Group, 2001, s. 222. Dostupné z: <http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.660.6210&rep=rep1&type=pdf>, vyhledáno 20. 8. 2020.
- 11 **Smith, G. C. – Pell, J. P.**: Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. *BMJ*, 2003, 327, s. 1459–1461.
- 12 **Annas, G. J. – Grodin, M. A.**: Reflections on the 70th Anniversary of the Nuremberg Doctors' Trial. *Am J Public Health*, 2018, 108, s. 10–12.
- 13 **White, R. M.**: Unraveling the Tuskegee Study of untreated syphilis. *Arch Intern Med*, 2000, 160, s. 585–598.
- 14 **Riis, P.**: Planning of scientific-ethical committees. *Br Med J*, 1977, 2, s. 1731–17314.
- 15 **Greenhalgh, T. – Howick, J. – Maskrey, N.**: Evidence Based Medicine Renaissance Group: Evidence based medicine: a movement in crisis? *BMJ*, 2014, 348, s. g3725.
- 16 **Heres, S. – Davis, J. – Maino, K., et al.**: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. *Am J Psychiatry*, 2006, 163, s. 185–194.
- 17 **Turner, E. H. – Matthews, A. M. – Linardatos, E., et al.**: Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med*, 2008, 358, s. 252–260.
- 18 **Montori, V. M. – Brito, J. P. – Ting, H. H.**: Patient-centered and practical application of new high cholesterol guidelines to prevent cardiovascular disease. *JAMA*, 2014, 311, s. 465–466.

Současná doporučení pro léčbu mnohočetného myelomu

MUDr. Hana Plonková | MUDr. Tomáš Jelínek, Ph.D. | MUDr. Tereza Popková | prof. MUDr. Roman Hájek, CSc.

Klinika hematologie, Fakultní nemocnice Ostrava, Lékařská fakulta Ostravské univerzity, Ostrava

- 1 **Moreau, P. – San Miguel, J. – Sonneveld, P., et al.**: ESMO Guidelines Committee: Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2017, 28, s. iv52–v61.
- 2 **Moreau, P. – Attal, M. – Facon, T.**: Frontline therapy of multiple myeloma. *Blood*, 2015, 125, s. 3076–3084.
- 3 **Roussel, M. – Lauwers-Cances, V. – Robillard, N., et al.**: Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. *J Clin Oncol*, 2014, 32, s. 2712–2717.
- 4 **Moreau, P. – Attal, M. – Hulin, C., et al.**: Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*, 2019, S0140-6736(19)31403-31405.
- 5 **Attal, M. – Lauwers-Cances, V. – Hulin, C., et al.**: Study IFM. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. *N Engl J Med*, 2017, 376, s. 1311–1320.
- 6 **Cavo, M. – Petrucci, M. T. – Di Raimondo, F., et al.**: Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: An intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial). *Blood*, 2016, 128, s. 991.
- 7 **Hájek, R. – Maisnar, V. – Krejčí, M., et al.**: Diagnostika a léčba mnohočetného myelomu. *Transf Hematol Dnes*, 2018, suppl. 1, s. 1–155.
- 8 **McCarthy, P. L. – Holstein, S. A. – Petrucci, M. T., et al.**: Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis. *J Clin Oncol*, 2017, 35, s. 3279–3289.

- 9 Durie, B. G. M. – Hoering, A. – Abidi, M. H., et al.: Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *Lancet*, 2017, 389, s. 519–527.
- 10 Facon, T. – Dimopoulos, M. A. – Dispenzieri, A., et al.: Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. *Blood*, 2018, 131, s. 301–310.
- 11 Mateos, M. V. – Cavo, M. – Blade, J., et al.: Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. *Lancet*, 2020, 395, s. 132–141.
- 12 Facon, T. – Kumar, S. – Plesner, T., et al.: Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. *N Engl J Med*, 2019, 380, s. 2104–2115.
- 13 Richardson, P. G. – Oriol, A. – Beksac, M., et al.: Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISM): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2019, 20, s. 781–794.
- 14 Dimopoulos, M. – Quach, H. – Mateos, M.-V., et al.: Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. *Lancet*, 2020, 396, s. 186–197.
- 15 Mateos, M.-V. – Sonneveld, P. – Hungria, V., et al.: Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. *Clin Lymph Myel Leuk*, 2020, 20, s. 509–518.
- 16 Dimopoulos, M. A. – Moreau, P. – Palumbo, A., et al.: Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open label, multicentre study. *Lancet Oncol*, 2016, 17, s. 27–38.
- 17 Sonneveld, P. – Zweegman, S. – Cavo, M., et al.: Carfilzomib, pomalidomide and dexamethasone (KPd) in patients with multiple myeloma refractory to bortezomib and lenalidomide, the EMN011 trial. *Blood*, 2018, s. 801–801.
- 18 Krishnan, A. – Kapoor, P. – Palmer, J. M., et al.: Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. *Leukemia*, 2018, 32, s. 1567–1574.
- 19 Siegel, D. S. – Schiller, G. J. – Samaras, C. J., et al.: Pomalidomide + low-dose dexamethasone + daratumumab in relapsed and/or refractory multiple myeloma after lenalidomide-based treatment failure. *Blood*, 2018, s. 3271–3271.
- 20 Dimopoulos, M. A. – Oriol, A. – Nahi, H., et al.: Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*, 2016, 375, s. 1319–1331.
- 21 Siegel, D. S. – Dimopoulos, M. A. – Ludwig, H., et al.: Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. *J Clin Oncol*, 2018, 36, s. 728–734.
- 22 Moreau, P. – Masszi, T. – Grzasko, N., et al.: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*, 2016, 374, s. 1621–1634.
- 23 Lonial, S. – Dimopoulos, M. – Palumbo, A., et al.: Elotuzumab therapy for relapsed or refractory multiple myeloma. *N Engl J Med*, 2015, 373, s. 621–631.
- 24 Bahis, N. J. – Dimopoulos, M. A. – White, D. J., et al.: Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. *Leukemia*, 2020, 34, s. 1875–1884.
- 25 San Miguel, J. – Weisel, K. – Moreau, P., et al.: Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. *Lancet Oncol*, 2013, 14, s. 1055–1066.
- 26 Attal, M. – Richardson, P. G. – Rajkumar, S. V., et al.: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet*, 2019, 394, s. 2096–2107.
- 27 Dimopoulos, M. A. – Dytfield, D. – Grosicki, S., et al.: Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. *N Engl J Med*, 2018, 379, s. 1811–1822.
- 28 Chari, A. – Suvannasankha, A. – Fay, J. W., et al.: Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. *Blood*, 2017, 130, s. 974–981.
- 29 Chari, A. – Vogl, D. T. – Gavriatopoulou, M., et al.: Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. *N Engl J Med*, 2019, 381, s. 727–738.
- 30 San-Miguel, J. F. – Hungria, V. T. M. – Yoon, S.-S., et al.: Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. *Lancet Oncol*, 2014, 15, s. 1195–1206.
- 31 Richardson, P. G. – Brincken, S. – Voorhees, P., et al.: Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. *Lancet Haematol*, 2020, 7, s. e395–e407.
- 32 Raje, N. – Berdeja, J. – Lin, Y., et al.: Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. *N Engl J Med*, 2019, 380, s. 1726–1737.
- 33 Moreau, P. – Harrison, S. – Cavo, M., et al.: Updated analysis of Bellini, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. *Blood*, 2019, 134, suppl. 1, s. 1888.

Management léčby asymptomatického (smoldering) mnohočetného myelomu; strategie „watch and wait“ u monoklonálních gamapatií

MUDr. Denisa Nováková | doc. MUDr. Jakub Radocha, Ph.D. IV. interní hematologická klinika LF UK a FN v Hradci Králové

- 1 Brigle, K. – Rogers, B.: Pathobiology and diagnosis of multiple myeloma. *Semin Oncol Nurs*, 2017, 33, s. 225–236.
- 2 Vydra, J. – Novák, J. – Lauermannová, M.: *Hematologie v kostce*. Praha, Mladá fronta, 2019.
- 3 International Myeloma Working Group: Updated criteria for the diagnosis of multiple myeloma. *Lancet Oncology*, 2014, 15, s. e538–e548.
- 4 Rajkumar, S. V. – Kumar, S.: Multiple myeloma: diagnosis and treatment. *Symposium on neoplastic hematology and medical oncology*, 2016, 91, s. 101–119.
- 5 Mateos, M.-V. – González-Calle, V.: Smoldering multiple myeloma: who and when to treat. *Clin Lymphoma Myeloma Leuk*, 2017, 17, s. 716–722.
- 6 Hill, E. – Dew, A. – Kazandjian, D.: State of the science in smoldering myeloma: should we be treating in the clinic? *Seminars in Oncology*, 2019, 46, s. 112–120.
- 7 Bladé, J. – Dimopoulos, M. – Rosiñol, L., et al.: Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. *J Clin Oncol*, 2010, 28, s. 690–697.
- 8 Hájek, R., et al.: Diagnostika a léčba mnohočetného myelomu. *Transfúze a hematologie dnes*, 2018, 24, suppl. 1, s. 7–23.
- 9 Mateos, M.-V. – Bladé, J. – Lahuerta, J.-J., et al.: Management of smoldering myeloma: recommendations of the Spanish Myeloma Group. *Medicina Clínica*, 2017, 148, s. 517–523.
- 10 Klincová, M. – Mikulášová, A. – Říhová, L., et al.: Prognóza vysoko rizikové skupiny monoklonální gamapatie nejasného významu (MGUS) a asymptomatického mnohočetného myelómu (SMM). *Onkologie*, 2011, 5, s. 146–150.
- 11 Rosiñol, L. – Bladé, J. – Esteve, J., et al.: Smoldering multiple myeloma: natural history and recognition of an evolving type. *Br J Haematol*, 2003, 123, s. 631–636.
- 12 Hájek, R. – Sandecka, V. – Špička, I., et al.: Identification of patients with smoldering multiple myeloma at ultra-high risk of progression using serum parameters: The Czech Myeloma Group Model. *Br J Haematol*, 2020, 190, s. 189–197.

Strategie „watch and wait“ u pacientů s chronickou lymfocytární leukémií

MUDr. Dominika ěcsiová | MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové

- 1 Hallek, M., et al.: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*, 2018, 131, s. 2745–2760.
- 2 Herling, C. D., et al.: Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. *Leukemia*, 2020.
- 3 Ma, S. – Plataniotis, L. C.: Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia? *Expert Opin Pharmacother*, 2018, 19, s. 1171–1175.
- 4 Pflug, N., et al.: Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. *Blood*, 2014, 124, s. 49–62.
- 5 Shustik, C., et al.: Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. *Hematol Oncol*, 1988, 6, s. 7–12.
- 6 Dighiero, G., et al.: Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. *N Engl J Med*, 1998, 338, s. 1506–1514.
- 7 Hoehstetter, M. A., et al.: Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. *Leukemia*, 2017, 31, s. 2833–2837.
- 8 Langerbeins, P., et al.: The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. *Future Oncol*, 2015, 11, s. 1895–1903.
- 9 Langerbeins, P., et al.: Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 2 double-blind randomized CLL12 trial. In: Langerbeins, P. (ed.): EHA, 2019.
- 10 Moia, R., et al.: Precision medicine management of chronic lymphocytic leukemia. *Cancers*, 2020, 12.

Má stále smysl strategie přístupu sledování „watch and wait“ u lymfomů?

MUDr. Alice Sýkorová, Ph.D. | MUDr. David Belada, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové

- 1 Non-Hodgkin lymphoma B-cell subtypes | Seattle Cancer Care Alliance. Dostupné z: <https://www.seattlecca.org/diseases/non-hodgkins-lymphoma/non-hodgkins-lymphoma-facts/types/b-cell-subtypes>, vyhledáno 9. 8. 2020.
- 2 Dostupné z: <https://www.ils.org/lymphoma/non-hodgkin-lymphoma/diagnosis/nhl-subtypes>, vyhledáno 14. 8. 2020.
- 3 Coiffier, B. – Thieblemont, C. – Van Den Neste, E., et al.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood*, 2010, 116, s. 2040–2045.
- 4 Brice, P. – Bastion, Y. – Lepage, E., et al.: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol*, 1997, 15, s. 1110–1117.
- 5 Kastritis, E. – Leblond, V. – Dimopoulos, M. A., et al.: Waldenström's macroglobulinemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *An Oncol*, 2018, 29, s. iv41–iv50.
- 6 Dimopoulos, M. A. – Kastritis, E.: How I treat Waldenström macroglobulinemia. *Blood*, 2019, 134, s. 2022–2035.
- 7 Ardeshtna, K. M. – Smith, P. – Norton, A., et al.: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. *Lancet*, 2003, 362, s. 516–522.
- 8 Rezvani, A. R. – Sandmaier, B. M.: Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes. *Curr Opin Hematol*, 2013, 20, s. 509–514.
- 9 Dostupné z: <https://lymphomanewstoday.com/indolent-lymphoma/>, vyhledáno 14. 8. 2020.

- 10 Solal-Céligny, P. – Bellei, M. – Marcheselli, L., et al.: Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. *J Clin Oncol*, 2012, 30, s. 3848–3853.
- 11 Armitage, J. O. – Longo, D. L.: Is watch and wait still acceptable for patients with low-grade follicular lymphoma? *Blood*, 2016, 127, s. 2804–2808.
- 12 Young, R. C. – Longo, D. L. – Glatstein, E., et al.: The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. *Semin Hematol*, 1988, 25, s. 11–16.
- 13 Al-Tourah, A. J. – Gill, K. K. – Chhanabhai, M., et al.: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. *J Clin Oncol*, 2008, 26, s. 5165–5169.
- 14 Ardeshta, K. M. – Qian, W. – Smith, P., et al.: Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. *Lancet Oncol*, 2014, 15, s. 424–435.
- 15 Jegalian, A. G. – Eberle, F. C. – Pack, S. D., et al.: Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. *Blood*, 2011, 118, s. 2976–2984.
- 16 Jain, P. – Wang, M.: Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. *Am J Hematol*, 2019, 94, s. 710–725.
- 17 Furtado, M. – Rule, S.: Indolent mantle cell lymphoma. *Haematologica*, 2011, 96, s. 1086–1088.
- 18 Abrisqueta, P. – Scott, D. W. – Slack, G. W., et al.: Observation as the initial management strategy in patients with mantle cell lymphoma. *Ann Oncol*, 2017, 28, s. 2489–2495.
- 19 Ye, H. – Desai, A. – Zeng, D., et al.: Smoldering mantle cell lymphoma. *J Exp Clin Cancer Res*, 2017, 36, s. 185.
- 20 Royo, C. – Navarro, A. – Clot, G., et al.: Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. *Leukemia*, 2012, 26, s. 1895–1898.
- 21 Swerdlow, S. H. – Campo, E. – Pileri, S. A., et al.: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*, 2016, 127, s. 2375–2390.
- 22 Carvajal-Cuenca, A. – Sua, L. F. – Silva, N. M., et al.: In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. *Haematologica*, 2012, 97, s. 270–278.
- 23 Adam, P. – Schiefer, A. – Prill, S., et al.: Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues. *Mod Pathol*, 2012, 25, s. 1629–1636.
- 24 Alexanian, R. – Weber, D. – Delasalle, K., et al.: Asymptomatic Waldenström's macroglobulinemia. *Semin Oncol*, 2003, 30, s. 206–210.
- 25 Advani, P. – Paulus, A. – Alilawadhi, S.: Updates in prognostication and treatment of Waldenström's macroglobulinemia. *Hematology/Oncology and Stem Cell Therapy*, 2019, 12, s. 179–188.
- 26 Treon, S. P. – Xu, L. – Yang, G., et al.: MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. *N Engl J Med*, 2012, 367, s. 826–833.
- 27 Gertz, M. A.: Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. *Am J Hematol*, 2019, 94, s. 266–276.
- 28 Oza, A. – Rajkumar, S. V.: Waldenström's macroglobulinemia: prognosis and management. *Blood Cancer J*, 2015, 5, s. e394.
- 29 Garcia-Sanz, R. – Montoto, S. – Torquebrada, A., et al.: Waldenström macroglobulinemia: presenting features and outcome in a series with 217 cases. *Br J Haematol*, 2001, 115, s. 575–582.
- 30 Morel, P. – Duhamel, A. – Gobbi, P., et al.: International prognostic scoring system for Waldenström macroglobulinemia. *Blood*, 2009, 113, s. 4163–4170.
- 31 Kyle, R. A. – Treon, S. P. – Alexanian, R., et al.: Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. *Semin Oncol*, 2003, 30, s. 116–120.
- 32 Leblond, V. – Kastritis, E. – Advani, R., et al.: Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. *Blood*, 2016, 128, s. 1321–1328.
- 33 Abeykoon, J. P. – Zanwar, S. – Ansell, S. M., et al.: Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. *Am J Hematol*, 2018, 93, s. 1384–1393.
- 34 Hallek, M. – Cheson, B. D. – Catovsky, D., et al.: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood*, 2018, 131, s. 2745–2760.

Nové léčebné postupy u chronické lymfocytární leukemie

MUDr. Martin Špaček, Ph.D. I. interní klinika – klinika hematologie, VFN a 1. LF UK, Praha

- 1 Hallek, M., et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood*, 2008, 111, s. 5446–5456.
- 2 Thompson, P. A., et al.: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. *Blood*, 2016, 127, s. 303–309.
- 3 Eichhorst, B., et al.: First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. *Lancet Oncol*, 2016, 17, s. 928–942.
- 4 Goede, V., et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med*, 2014, 370, s. 1101–1110.
- 5 Špaček, M., et al.: Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. *Leuk Res*, 2019, 79, s. 17–21.
- 6 Munir, T., et al.: Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. *Am J Hematol*, 2019, 94, s. 1353–1363.
- 7 Furman, R. R., et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med*, 2014, 370, s. 997–1007.
- 8 Seymour, J. F., et al.: Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med*, 2018, 378, s. 1107–1120.
- 9 Flinn, I. W., et al.: The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. *Blood*, 2018, 132, s. 2446–2455.

Léčba chronické myeloidní leukemie – současnost a výhledy

MUDr. Hana Klamová Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha

- 1 Vardiman, J. W. – Melo, J. V. – Baccarani, M., et al.: Chronic myeloid leukaemia, BCR-ABL1-positive. In: Swerdlow, S. H. – Campo, E. – Lee, H. N., et al.: *WHO classification of tumours of haematopoietic and lymphoid tissue*. Lyon, International Agency for Research on Cancer, 2017, s. 30–36.
- 2 Drucker, B. J. – Guilhot, F. – O'Brien, S. G., et al.: Five-year follow-up patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med* 2000, 355, s. 2408–2417.
- 3 Hehlmann, R. – Hochhaus, A. – Baccarani, M., et al.: On behalf of the European Leukemia Net. Chronic myeloid leukemia. *Lancet*, 2007, 370, s. 342–350.
- 4 Huang, X. – Cortes, J. – Kantarjian, H.: Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor. *Cancer*, 2012, 118, s. 3121–3127.
- 5 Baccarani, M. – Deininger, M. W. – Rosti, G., et al.: European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, 2013, 122, s. 872–884.
- 6 Mayer, J. (ed.): *Léčebné postupy v hematologii: doporučení České hematologické společnosti České lékařské společnosti Jana Evangelisty Purkyně*. Praha: Česká hematologická společnost České lékařské společnosti J. E. Purkyně, 2016.
- 7 Etienne, G. – Rea, D. – Guilhot, J., et al.: Long-Term Follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. *J Clin Oncol*, 2017, 35, s. 298.
- 8 Saussele, S. – Richter, J. – Hochhaus, A., et al.: The concept of treatment-free remission in chronic myeloid leukemia. *Leukemia*, 2016, 30, s. 1638–1647.
- 9 Saussele, S. – Richter, J. – Guilhot, J., et al.: Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EU-RO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. *Lancet Oncol*, 2018, 19, s. 747–757.
- 10 Zemanová, K. – Žižková, H. – Jurček, T., et al.: Chronická myeloidní leukemie – standardizace molekulárního monitorování hladiny transkriptů BCR-ABL1 v České republice. *Transfuzie Hematol dnes*, 2001, 22, s. 56–64.
- 11 Holyoake, L. – Vetrie, D.: The chronic myeloid leukemia stem cell: stemming the tide or persistence. *Blood*, 2017, 129, s. 1595–1606.
- 12 Hjorth-Hansen, H. – Richter, J., et al.: Safety and efficacy of the combination of pegylated-alpha2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. *Leukemia*, 2016, 30, s. 1853–1860.
- 13 Hochhaus, A. – Baccarani, M. – Silver, R. T., et al.: European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*, 3. 3. 2020, DOI: 10.1038/s41375-020-0776-2.

Gemtuzumab ozogamicin

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Damle, N. K. – Frost, P.: Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. *Curr Opin Pharmacol*, 2003, 3, s. 386–390.
- 2 Ricart, A. D.: Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. *Clin Cancer Res*, 2011, 17, s. 6417–6427.
- 3 Baron, J. – Wang, E. S.: Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. *Expert Rev Clin Pharmacol*, 2018, 11, s. 549–559.
- 4 Larson, R. A. – Sievers, E. L. – Stadtmauer, E. A., et al.: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. *Cancer*, 2005, 104, s. 1442–1452.
- 5 Bross, P. F. – Beitz, J. – Chen, G., et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. *Clin Cancer Res*, 2001, 7, s. 1490–1496.
- 6 Arceci, R. J. – Sande, J. – Lange, B., et al.: Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. *Blood*, 2005, 106, s. 1183–1188.
- 7 Taksin, A. L. – Legrand, O. – Raffoux, E., et al.: High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. *Leukemia*, 2007, 21, s. 66–71.
- 8 Petersdorf, S. H. – Kopecky, K. J. – Slovak, M., et al.: A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. *Blood*, 2013, 121, s. 4854–4860.
- 9 Castaigne, S. – Pautas, C. – Terre, C., et al.: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. *Lancet*, 2012, 379, s. 1508–1516.
- 10 Jen, E. Y. – Ko, C. W. – Lee, J. E., et al.: FDA Approval: Gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia. *Clin Cancer Res*, 2018, 24, s. 3242–3246.
- 11 Hills, R. K. – Castaigne, S. – Appelbaum, F. R., et al.: Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. *Lancet Oncol*, 2014, 15, s. 986–996.
- 12 Amadori, S. – Suciu, S. – Selleslag, D., et al.: Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. *J Clin Oncol*, 2016, 34, s. 972–979.
- 13 SPC MYLOTARG 5 mg prášek pro koncentrát pro infuzní roztok. Zdroj: www.sukl.cz.

Primární lymfom centrální nervové soustavy – aktuální možnosti léčby

MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FN KV a 3. LF UK, Praha

- Mocikova, H. – Pytlík, R. – Sykorova, A., et al.: Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. *Leuk Lymphoma*, 2016, 57, s. 2777–2783.
- Camilleri-Broët, S. – Crinière, E. – Broët, P., et al.: A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. *Blood*, 2006, 107, s. 190–196.
- Bataille, B. – Delwail, V. – Menet, E., et al.: Primary intracerebral malignant lymphoma: report of 248 cases. *J Neurosurg*, 2000, 92, s. 261–266.
- Ferreri, A. J. – Blay, J. Y. – Reni, M., et al.: Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. *J Clin Oncol*, 2003, 21, s. 266–272.
- Abrey, L. E. – Ben-Porat, L. – Panageas, K. S., et al.: Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. *J Clin Oncol*, 2006, 24, s. 5711–5715.
- Jahnke, K. – Thiel, E. – Martus, P., et al.: German Primary Central Nervous System Lymphoma Study Group: Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. *J Neurooncol*, 2006, 80, s. 159–165.
- Langner-Lemercier, S. – Houillier, C. – Soussain, C., et al.: Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. *Neuro Oncol*, 2016, 18, s. 1297–1303.
- Shibamoto, Y. – Ogino, H. – Hasegawa, M., et al.: Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. *Int J Radiat Oncol Biol Phys*, 2005, 62, s. 809–813.
- Schmitt, A. M. – Herbrand, A. K. – Christopher, P., et al.: Rituximab in primary central nervous system lymphoma – a systematic review and meta-analysis. *Hematol Oncol*, 2019, 37, s. 548–557.
- Omuro, A. – Correa, D. D. – DeAngelis, L. M., et al.: R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. *Blood*, 2015, 125, s. 1403–1410.
- Illerhaus, G. – Kasenda, B. – Ihorst, G., et al.: High-dose chemotherapy with autologous haematopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. *Lancet Haematology*, 2016, 3, s. 388–397.
- Ferreri, A. J. M. – Cwynarski, K. – Pulczynski, E., et al.: Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemioimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematol*, 2017, 4, s. 510–523.
- Houillier, C. – Taillandier, L. – Dureau, S., et al.: Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. *J Clin Oncol*, 2019, 37, s. 823–833.
- Mendez, J. S. – Ostrom, Q. T. – Gittleman, H.: The elderly left behind: changes in survival trends of primary central nervous system lymphoma over the past 4 decades. *Neuro Oncol*, 2018, 20, s. 687–694.
- Zhu, J. J. – Gerstner, E. R. – Engler, D. A., et al.: High-dose methotrexate for elderly patients with primary CNS lymphoma. *Neuro Oncol*, 2009, 11, s. 211–215.
- Soussain, C. – Choquet, S. – Blonski, M., et al.: Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) network. *Eur J Cancer*, 2019, 117, s. 121–130.
- Ghesquieres, H. – Chevrier, M. – Laadhari, M., et al.: Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). *Ann Oncol*, 2019, 30, s. 621–628.

Nehodgkinské lymfomy dětí a dospívajících: současné možnosti léčby a výhledy

MUDr. Edita Kabičková, Ph.D. Klinika dětské hematologie a onkologie 2. LF UK a FN v Motole, Praha

- Meinhardt, A. – Burkhardt, B. – Zimmermann, M., et al.: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. *J Clin Oncol*, 2010, 28, s. 3115–3121.
- Woessmann, W. – Seidemann, K. – Mann, G., et al.: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM 95. *Blood*, 2005, 105, s. 948–958.
- Reiter, A. – Schrappe, M. – Ludwig, W. D., et al.: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. *Blood*, 2000, 95, s. 416–421.
- Bonn, B. R. – Rohde, M. – Zimmermann, M., et al.: Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. *Blood*, 2013, 121, s. 3153–3160.
- Seidemann, K. – Tiemann, M. – Schrappe, M., et al.: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. *Blood*, 2001, 97, s. 3699–3706.
- Mossé, Y. P. – Voss, S. D. – Lim, M. S., et al.: Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study. *J Clin Oncol*, 2017, 35, s. 3215–3221.

Jak dál s imunitní trombocytopenií ve světle nejnovějších doporučení

MUDr. Eva Konířová | prof. MUDr. Marek Trněný, CSc. I. interní klinika – klinika hematologie VFN a 1. LF UK, Praha

- Provan, D., et al.: International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood*, 2010, 115, s. 168–186.
- Neunert, C., et al.: The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood*, 2011, 117, s. 4190–4207.
- Provan, D., et al.: Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv*, 2019, 3, s. 3780–3817.
- Neunert, C., et al.: American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv*, 2019, 3, s. 3829–3866.
- Stasi, R., et al.: Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. *Thromb Haemost*, 2008, 99, s. 4–13.
- Houwerzijl, E. J., et al.: Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. *Blood*, 2004, 103, s. 500–506.
- McMillan, R., et al.: Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. *Blood*, 2004, 103, s. 1364–1369.
- Li, J. – Xia, Y. – Kuter, D. J.: Interaction of thrombopoietin with the platelet c-Mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. *Br J Haematol*, 1999, 106, s. 345–356.
- Kuter, D. J. – Phil, D. – Gernsheimer, T. B.: Thrombopoietin and platelet production in chronic immune thrombocytopenia. *Hematol Oncol Clin North Am*, 2009, 23, s. 1193–1211.
- Nichol, J. L.: Endo endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention. *Stem Cells*, 1998, 16, suppl. 2, s. 165–175.
- Kuter, D. J., et al.: Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. *Br J Haematol*, 2013, 161, s. 411–423.
- Saleh, M. N., et al.: Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. *Blood*, 2013, 121, s. 537–545.
- Kuter, D. J., et al.: Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. *Br J Haematol*, 2019, 185, s. 503–513.
- Puavilai, T., et al.: Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. *Br J Haematol*, 2020, 188, s. 450–459.
- Newland, A., et al.: Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. *Br J Haematol*, 2016, 172, s. 262–273.
- Bao, W., et al.: Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. *Blood*, 2010, 116, s. 4639–4645.
- Godeau, B., et al.: Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. *Blood*, 2008, 112, s. 999–1004.
- Patel, V. L., et al.: Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. *Blood*, 2012, 119, s. 5989–5995.
- Bussell, J. B., et al.: Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. *Am J Hematol*, 2018, 93, s. 921–930.
- Rodriguez Nuñez, R. M., et al.: Use of romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description. *Platelets*, 2020, 31, s. 403–406.
- Bussell, J. B., et al.: Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. *Lancet Haematol*, 2015, 2, s. e315–e325.
- Grainger, J. D., et al.: Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. *Lancet*, 2015, 386, s. 1649–1658.
- Tarantino, M. D., et al.: Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. *Lancet*, 2016, 388, s. 45–54.
- Bussell, J. B., et al.: A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. *Blood*, 2011, 118, s. 28–36.
- Elalfy, M. S., et al.: Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. *Ann Hematol*, 2011, 90, s. 1341–1344.
- Oved, J. H., et al.: Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexamethasone. *J Pediatr*, 2017, 191, s. 225–231.
- Newland, A., et al.: Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. *Am J Hematol*, 2020, 95, s. 178–187.
- Kuter, D. J., et al.: Safety and efficacy of rilzabrutinib (PRN 1008), an oral bruton tyrosine kinase inhibitor, in relapsed/refractory patients with primary or secondary immune thrombocytopenia: phase I/II adaptive study. Abstr. S316, 25th Congress of the European Hematology Association, virtual edition, 4th ven 2020, s. 11–21.
- Fan, A., et al.: Selective immunoproteasome inhibitor, KZR-616, a novel therapy for autoimmune hemolytic anemia and immune thrombocytopenia: biomarker activity and phase II clinical trial in progress (Marina). Abstr. S318, 25th Congress of the European Hematology Association, virtual edition, 4th ven 2020, s. 11–21.
- Bussell, J. B., et al.: A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. *Blood*, 2014, 123, s. 3887–3894.
- Jurczak, W., et al.: Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. *Br J Haematol*, 2018, 183, s. 479–490.

Terapeutické využití imunoglobulinů

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Chapel, H. – Lucas, M. – Lee, M., et al.: Common variable immunodeficiency disorders: division into distinct clinical phenotypes. *Blood*, 2008, 112, s. 277–286.
- 2 Aledort, L. M.: The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline. *Haemophilia*, 2016, 22, s. 676–683.
- 3 Abrahamsen, T. G. – Sandersen, H. – Bustnes, A.: Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. *Pediatrics*, 1996 98, s. 1127–1131.
- 4 Gardulf, A. – Nicolay, U. – Math, D., et al.: Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. *J Allergy Clin Immunol*, 2004, 114, s. 936–942.
- 5 Berger, M.: Subcutaneous immunoglobulin replacement in primary immunodeficiencies. *Clin Immunol*, 2004, 112, s. 1–7.
- 6 Milota, T. – Bloomfield, M. – Kralickova, P., et al.: Czech Hizentra non-interventional study with rapid push: efficacy, safety, tolerability, and convenience of therapy with 20% subcutaneous immunoglobulin. *Clin Ther*, 2019, 41, s. 2231–2238.

Dystymie – psychická porucha s převážně negativním hodnocením všeho prožitého

prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno

- 1 Adam, Z. – Klimeš, J. – Pour, L., et al.: *Maligní onemocnění, psychika a stres*. Praha, Grada Publishing, 2019.
- 2 World Health Organization. Division of Mental Health and Prevention of Substance Abuse: Identification of dysthymia in neurological disorders: report on the meeting of principal investigators involved in the field trial. Classification of dysthymia and related conditions in neurological disorders. 1998. Dostupné z: <https://apps.who.int/iris/handle/10665/63955>, vyhledáno 14. 5. 2020.
- 3 Patel, R. K. – Rose, G. M.: Persistent Depressive Disorder (Dysthymia). Treasure Island (FL), StatPearls Publishing, 2019. Dostupné z: <http://www.ncbi.nlm.nih.gov/books/NBK541052/>, vyhledáno 4. 5. 2019.
- 4 Gureje, O.: Dysthymia in a cross-cultural perspective. *Curr Opin Psychiatry*, 2011, 24, s. 67–71.
- 5 Tamburrino, M. B. – Lynch, D. J. – Nagel, R. W., et al.: Primary care evaluation of mental disorders (PRIME-MD) screening for minor depressive disorder in primary care. *Prim Care Companion J Clin Psychiatry*, 2009, 11, s. 339–343.
- 6 Höschel, C.: Dysthymie – cíl specifické terapeutické intervence? Nový přístup v léčbě dysthymie. Praha, Sanofi-Synthelabo, 2002, s. 6–7.
- 7 Anders, M.: Dysthymie. *Practicus*, 2005, 4, s. 46–48.
- 8 Viewegh, M.: *Báječná léta pod psa*. Petrov, Brno, 2002.
- 9 Libigerová, E.: Dysthymie – trvalá afektivní porucha na pomezí poruch osobnosti a poruch nálady. *Psychiatrie*, 2006, 10, s. 27–34.
- 10 Libigerová, E.: Dysthymie – diagnostika a léčba. *Psychiatrie pro praxi*, 2006, 7, s. 90–93.
- 11 Praško, J.: *Dysthymie: příručka pro klinickou praxi*. Praha, Maxdorf, 2003.
- 12 Praško, J. – Herman, E. – Hovorka, J.: *Dysthymie a její léčba. Psychiatrie v medicíně a medicína v psychiatrii*. Praha, Galén, 2002, s. 195–198.
- 13 Praško, J. – Herman, E. – Hovorka, J.: Dysthymie a její léčba. *Psychiatrie*, 2003, 7, suppl. 2, s. 92–93.
- 14 Praško, J. – Sigmundová, Z. – Demlová, B.: Dysthymie. *Klinická psychiatrie*, 2011, s. 298–309.
- 15 Praško, J. – Herman, E. – Hovorka, J.: Dysthymie a její léčba – 1. díl. *Psychiatrie pro praxi*, 2002, 3, s. 265–270.
- 16 Praško, J. – Herman, E. – Hovorka, J.: Dysthymie a její léčba – 2. díl. *Psychiatrie pro praxi*, 2003, 4, s. 23–28.
- 17 Forgáčová, L.: „Double“ depresie, klinické charakteristiky a léčba. *Psychiatrie pro praxi*, 2003, 4, s. 60–61.
- 18 Douglas, J. – Olshaker, M.: *Lovec duší*. Frýdek-Místek, Alpress, 1997. Online ukázka dostupná z: <http://klimes.mysteria.cz/clanky/psychologie/douglas/douglas.htm>, vyhledáno 14. 5. 2020.
- 19 Klimeš, J.: *Partneři a rozchody*. Portál, Praha, 2005.
- 20 Schönknecht, P. – Hegerl, U.: Dysthymia. *Fortschr Neurol Psychiatr*, 2012, 80, s. 602–608.
- 21 Brieger, P.: Subaffective disorders: dysthymia and cyclothymia. *MMW Fortschr Med*, 2010, 152, s. 31–33.
- 22 Schmauss, M. – Messer, T.: Dysthymia. *Fortschr Neurol Psychiatr*, 2005, 73, s. 415–424; 425–426.
- 23 Klein, D. N. – Santiago, N. J.: Dysthymia and chronic depression: introduction, classification, risk factors, and course. *J Clin Psychol*, 2003, 59, s. 807–816.
- 24 Benca, R. M. – Peterson, M. J.: Insomnia and depression. *Sleep Med*, 2008, 9, suppl. 1, s. S3–S9.
- 25 Levkovitz, Y. – Tedeschini, E. – Papakostas, G. I.: Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. *J Clin Psychiatry*, 2011, 72, s. 509–514.
- 26 von Wolff, A. – Hölzel, L. P. – Westphal, A., et al.: Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. *J Affect Disord*, 2013, 144, s. 7–15.